Tamibarotene for the Treatment of Bronchiolitis Obliterans Associated With Chronic Graft-vs-Host Disease

Chest: The Journal of Circulation, Respiration and Related Systems

Ken Ishiyama^2¹  Satoshi Watanabe^1² 

[1] Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan^2;Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan^1

关键词: bronchiolitis obliterans;    graft-vs-host disease;    tamibarotene;    allo-HSCT;    allogeneic hematopoietic stem cell transplantation;    APL;    acute promyelocytic leukemia;    BO;    bronchiolitis obliterans;    cGVHD;    chronic graft-vs-host disease;   

DOI  :  10.1016/j.chest.2018.08.1052

学科分类：呼吸医学

来源: American College of Chest Physicians

【 摘 要 】

Bronchiolitis obliterans (BO) is a significant life-threatening complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is associated with increased morbidity and mortality. BO responds poorly to corticosteroids or immunosuppressants, and there are currently no established treatment approaches. We herein describe a patient with biopsy-proven BO after allo-HSCT who was successfully treated with tamibarotene, a novel synthetic retinobenzoic acid. Tamibarotene led to a dramatic improvement in lung function as well as cutaneous manifestations of chronic graft-vs-host disease. A large prospective clinical trial is therefore warranted to confirm the efficacy of tamibarotene in BO.

【 授权许可】

CC BY